Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2. Tsutani Y, Goldman JW, Dacic S, Yatabe Y, et al. Clin Lung Cancer 2023;24:376-380.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tsutani Y, Goldman JW, Dacic S, Yatabe Y, et al. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2. Clin Lung Cancer 2023;24:376-380.
PMID: 36872181